Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933702 | 0.86 | NPC1 (0.48) | RAB9ANPC1ATMALDH1A1MEN1 | |
| SCHEMBL1933083 | 0.85 | ALDH1A1 (0.59) | RAB9AALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14452333 | 0.83 | RAB9A (0.50) | RAB9ANPC1ATMALDH1A1MEN1 | |
| SCHEMBL12553697 | 0.83 | RAB9A (0.45) | RAB9ANPC1ATMALDH1A1MEN1 | |
| SCHEMBL25385568 | 0.81 | NPC1 (0.53) | RAB9ANPC1ATMALDH1A1CNR1 | |
| SCHEMBL14749180 | 0.81 | RAB9A (0.53) | RAB9ANPC1ATMALDH1A1MEN1 | |
| SCHEMBL12553696 | 0.81 | NPC1 (0.53) | RAB9ANPC1ATMMAPTL3MBTL1 | |
| SCHEMBL9221435 | 0.79 | ALDH1A1 (0.56) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL27026756 | 0.79 | MAPT (0.53) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14743630 | 0.78 | RAB9A (0.53) | RAB9ANPC1ATMALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2582699-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012143329-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | RAB9A 3462/4885NPC1 4595/4885ATM 759/4885 |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | TTBK1, BUB1, TTK | RAB9A 2473/4885NPC1 1638/4885ATM 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.